These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36863285)

  • 1. Naloxone expansion is not associated with increases in adolescent heroin use and injection drug use: Evidence from 44 US states.
    Bruzelius E; Cerdá M; Davis CS; Jent V; Wheeler-Martin K; Mauro CM; Crystal S; Keyes KM; Samples H; Hasin DS; Martins SS
    Int J Drug Policy; 2023 Apr; 114():103980. PubMed ID: 36863285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
    Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC
    Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone laws facilitate the establishment of overdose education and naloxone distribution programs in the United States.
    Lambdin BH; Davis CS; Wheeler E; Tueller S; Kral AH
    Drug Alcohol Depend; 2018 Jul; 188():370-376. PubMed ID: 29776688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do naloxone access laws affect perceived risk of heroin use? Evidence from national US data.
    Kelly BC; Vuolo M
    Addiction; 2022 Mar; 117(3):666-676. PubMed ID: 34617356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018.
    Lee B; Zhao W; Yang KC; Ahn YY; Perry BL
    JAMA Netw Open; 2021 Feb; 4(2):e2036687. PubMed ID: 33576816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changing landscape of naloxone availability in the United States, 2011 - 2017.
    Freeman PR; Hankosky ER; Lofwall MR; Talbert JC
    Drug Alcohol Depend; 2018 Oct; 191():361-364. PubMed ID: 30195192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a 'moral hazard' associated with naloxone supply.
    Tse WC; Djordjevic F; Borja V; Picco L; Lam T; Olsen A; Larney S; Dietze P; Nielsen S
    Int J Drug Policy; 2022 Feb; 100():103513. PubMed ID: 34798434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of adults reporting illicitly manufactured fentanyl or heroin use or prescription opioid misuse in the United States, 2019.
    Jiang X; Guy GP; Dunphy C; Pickens CM; Jones CM
    Drug Alcohol Depend; 2021 Dec; 229(Pt A):109160. PubMed ID: 34740067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Legal changes to increase access to naloxone for opioid overdose reversal in the United States.
    Davis CS; Carr D
    Drug Alcohol Depend; 2015 Dec; 157():112-20. PubMed ID: 26507172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Legal requirements and recommendations to prescribe naloxone.
    Haffajee RL; Cherney S; Smart R
    Drug Alcohol Depend; 2020 Apr; 209():107896. PubMed ID: 32058248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid.
    Gertner AK; Domino ME; Davis CS
    Drug Alcohol Depend; 2018 Sep; 190():37-41. PubMed ID: 29966851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State legal innovations to encourage naloxone dispensing.
    Davis C; Carr D
    J Am Pharm Assoc (2003); 2017; 57(2S):S180-S184. PubMed ID: 28073688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.
    Guy GP; Haegerich TM; Evans ME; Losby JL; Young R; Jones CM
    MMWR Morb Mortal Wkly Rep; 2019 Aug; 68(31):679-686. PubMed ID: 31393863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High occurrence of witnessing an opioid overdose in a sample of women who use heroin in Tanzania: Implications for overdose prevention.
    Saleem HT; Likindikoki S; Nonyane BAS; Mbwambo J; Latkin C
    Int J Drug Policy; 2021 Oct; 96():103287. PubMed ID: 33994309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose.
    Abouk R; Pacula RL; Powell D
    JAMA Intern Med; 2019 Jun; 179(6):805-811. PubMed ID: 31058922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonmedical Use of Prescription Opioids, Heroin Use, Injection Drug Use, and Overdose Mortality in U.S. Adolescents.
    Bohm MK; Clayton HB
    J Stud Alcohol Drugs; 2020 Jul; 81(4):484-488. PubMed ID: 32800085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with gaps in naloxone knowledge: evidence from a 2022 great plains survey.
    Cooper-Ohm S; Habecker P; Humeniuk R; Bevins RA
    Harm Reduct J; 2024 Feb; 21(1):37. PubMed ID: 38336722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of US states' adoption of naloxone access laws, 2001-2017.
    Bohler RM; Hodgkin D; Kreiner PW; Green TC
    Drug Alcohol Depend; 2021 Aug; 225():108772. PubMed ID: 34052687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin.
    Spector AL; Galletly CL; Christenson EA; Montaque HDG; Dickson-Gomez J
    BMC Public Health; 2022 Jul; 22(1):1387. PubMed ID: 35854278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combative Treatment for Carfentanil Epidemic.
    Konapur R; Searls N; Babcock CCK; Blough E; Patel I
    J Addict Nurs; 2019; 30(1):2-3. PubMed ID: 30829994
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.